ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Vivus Submits Qnexa Response To FDA; Meeting Set For January

DOW JONES NEWSWIRES Vivus Inc. (VVUS) said it has responded to the U.S. Food and Drug Administration's concerns about obesity drug Qnexa and has set a meeting for late January to discuss the company's latest effort to win its approval. The disclosure follows an FDA panel's positive recommendation last week of Orexigen Therapeutics Inc.'s (OREX) weight-loss drug Contrave. The FDA doesn't have to follow the panel's recommendation, but the positive vote puts Orexigen ahead of Vivus and Arena Pharmaceuticals Inc. (ARNA)--which received negative recommendations from similar panels earlier this year--by easing investor concerns that major clinical studies would be needed before approval. The FDA in October issued a "complete response letter" for Qnexa saying it couldn't approve the drug application in its current form. The agency asked the company for a comprehensive assessment of Qnexa's potential to cause birth defects and for Vivus to provide evidence that the product doesn't increase the risk for major adverse cardiovascular events. The company said the FDA didn't request a new clinical trial, but asked for two-year study results involving Qnexa to be submitted. "Submission of our briefing document and confirmation of our meeting with the FDA indicate the continued progress Vivus is making in seeking U.S. approval of Qnexa for the treatment of obesity," Chief Executive Leland Wilson said Tuesday. "We are confident in the data analyses we have compiled in the briefing document, and we look forward to our meeting with the FDA." Vivus shares closed Monday at $9.42 and were inactive premarket. The stock is up 45% this month amid the positive news on Orexigen's Contrave. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Arena (ARNA)
DateTimeHeadline
03/27/201507:59:45Arena Investors Need To Pay Attention To Competition
03/23/201508:49:56Arena Pharmaceuticals Could Have Better Luck In Quarter 2
03/23/201506:51:27Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
03/22/201512:56:03Biotech Stocks: 2 to Avoid, 1 to Buy
03/21/201505:11:59Orexigen - Contrave Scripts Up, Equity Down, Approval In Europe...
03/18/201517:46:50Statement of Changes in Beneficial Ownership (4)
03/16/201509:51:47Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
03/16/201508:27:08Who Will Be Orexigen's Ex-U.S. Partner? My Bet Is On Takeda
03/15/201520:45:03Orexigen - Contrave Scripts Rise Over 6%, But The Focus Is On...
03/13/201517:44:08Vivus - Qsymia Scripts Pass 11,000 For First Time In 2015
03/11/201508:26:11Arena Scripts Still Slower Than Needed - Are Downgrades In The...
03/10/201502:21:06Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep...
03/10/201502:07:01Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To...
03/09/201510:37:08Orexigen's Contrave Blunder Due To Weak Intellectual Property...
03/04/201517:55:55Statement of Changes in Beneficial Ownership (4)
03/03/201516:26:44Current Report Filing (8-k)
03/02/201520:07:03Arena's (ARNA) CEO Jack Lief on Q4 2014 Results - Earnings Call...
03/02/201516:01:00Arena Pharmaceuticals Provides Corporate Update and Reports Fourth...
03/01/201517:35:17Notable earnings after Mondayâs close
02/23/201511:00:10Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad